Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: oldirtybastard who wrote (157532)	5/6/2020 11:27:44 AM
From: oldirtybastard	Respond to of 218645

Also interesting though unrelated, since Mikovits mentioned it, this african sleeping sickness drug (suramin) for autism spectrum disorder has actually gone thru a Phase I/II trial. Then again, lots of drugs look good in Phase II ncbi.nlm.nih.gov

To: oldirtybastard who wrote (157532)	5/6/2020 12:33:19 PM
From: maceng2	Read Replies (3) \| Respond to of 218645

Things are multifactorial vs binary, Yes, in most cases. But when you are dealing with multinationals, and you lift a rock and find some bad news, you might find other co workers don't find the same results as you did. Just one of those things. Even in the United States of America. As Dr Judy Mikovitz explains in the video interview here. virutron.com The origin of the periodical, and the video, showing the subsequent historical record of problems with vaccines is of interest here. Mouse brains eh? well how unusual is that. But no one was able to replicate the data. yeah.... well there ya go. and there were no charges that stuck when she got thrown in jail? That is the data point of interest to me here. Forget the rest. Grand Jury stuff as far as I am concerned, all the rest of the data sets can be reviewed and replicated if necessary later. How many millions of Americans could be involved? It's a matter of reviewing the data sets by a trusted authority. That would exclude a lot of companies these days by the looks of things. Big Pharma might be in for a roasting in the near future, I wonder what will turn up?